Silence the Shame, is set to host a college empowerment summit to provide resources, support and inspiration to college ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

In head-to-head clinical trial, Chinese firm Akeso’s ivonescimab beat top-selling drug pembrolizumab sold as Keytruda by Merck. Ivonescimab reduced risk of tumour progression by 49%.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Summit Therapeutics Inc (SMMT) stock saw a decline, ending the day at $24.56 which represents a decrease of $-1.66 or -6.33% from the prior close of $26.22. The stock opened at $26.17 and touched a ...

Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising ...

The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 50% bearish. Among these notable ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Summit Therapeutics acquired rights to ivonescimab outside of China and Australia. With Keytruda sales up around $25 billion ...

Those following along with Summit Therapeutics Inc. (NASDAQ:SMMT) will no doubt be intrigued by the recent purchase of shares by Robert Duggan, Co-CEO & Executive Chairman of the company, who spent a ...

The biotech space is incredibly exciting, given that companies are investing heavily to treat and prevent diseases. In fact, ...